Payment overview · 2025
General Payments
$481.05
21 reported records · 11 companies
Healthcare provider profile · identity verified
David W Griffiths, MD
Allopathic & Osteopathic Physicians|Family Medicine · TULSA, OK · NPI 1366406076
Verified facts
What the public records show
CMS Open Payments records show David W Griffiths, MD received $481.05 in general payments during 2025 across 21 reported records.
Pharmacosmos Therapeutics Inc. accounted for 29.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Jardiance, Linzess, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $140.14 | 29.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $62.67 | 13.0% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $53.21 | 11.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $46.61 | 9.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.63 | 9.3% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $32.99 | 6.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.61 | 6.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.54 | 4.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.34 | 4.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.17 | 3.0% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $14.14 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $481.05 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $140.14 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $58.97 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $53.21 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $46.61 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $32.99 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.61 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.61 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.35 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.35 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 32 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
32 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
123 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 811 | 213 |
| Pantoprazole Sodium | Pantoprazole Sodium | 611 | 173 |
| Amlodipine Besylate | Amlodipine Besylate | 415 | 115 |
| Tizanidine Hcl | Tizanidine Hcl | 342 | 114 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 320 | 70 |
| Montelukast Sodium | Montelukast Sodium | 291 | 83 |
| Lisinopril | Lisinopril | 286 | 77 |
| Atenolol | Atenolol | 280 | 67 |
| Gabapentin | Gabapentin | 239 | 55 |
| Alprazolam | Alprazolam | 232 | 44 |
| Alendronate Sodium | Alendronate Sodium | 223 | 55 |
| Potassium Chloride | Potassium Chloride | 222 | 66 |
| Metformin Hcl | Metformin Hcl | 215 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 211 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 201 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 178 | 51 |
| Ezetimibe | Ezetimibe | 167 | 50 |
| Famotidine | Famotidine | 164 | 39 |
| Losartan Potassium | Losartan Potassium | 150 | 42 |
| Trazodone Hcl | Trazodone Hcl | 148 | 42 |
| Ozempic | Semaglutide | 143 | 23 |
| Allopurinol | Allopurinol | 134 | 32 |
| Tramadol Hcl | Tramadol Hcl | 132 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 131 | 34 |
| Temazepam | Temazepam | 129 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 127 | 74 |
| Azithromycin | Azithromycin | 125 | 94 |
| Eliquis | Apixaban | 123 | 21 |
| Finasteride | Finasteride | 121 | 33 |
| Furosemide | Furosemide | 120 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 117 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 104 | 28 |
| Mirtazapine | Mirtazapine | 101 | 21 |
| Carvedilol | Carvedilol | 95 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 87 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 33 |
| Doxepin Hcl | Doxepin Hcl | 84 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 29 |
| Memantine Hcl | Memantine Hcl | 82 | 21 |
| Valsartan | Valsartan | 81 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 26 |
| Donepezil Hcl | Donepezil Hcl | 75 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 15 |
| Ondansetron Odt | Ondansetron | 64 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 23 |
| Meclizine Hcl | Meclizine Hcl | 63 | 24 |
| Omeprazole | Omeprazole | 63 | 18 |
| Sertraline Hcl | Sertraline Hcl | 61 | 20 |
| Synthroid | Levothyroxine Sodium | 61 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 58 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 56 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 13 |
| Fluconazole | Fluconazole | 54 | 35 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 49 | 12 |
| Meloxicam | Meloxicam | 49 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 49 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 28 |
| Bupropion Xl | Bupropion Hcl | 48 | suppressed |
| Estradiol | Estradiol | 47 | 14 |
| Glipizide | Glipizide | 46 | 14 |
| Warfarin Sodium | Warfarin Sodium | 46 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 30 |
| Lovastatin | Lovastatin | 45 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 44 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 44 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 27 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | suppressed |
| Glimepiride | Glimepiride | 40 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 37 | suppressed |
| Amoxicillin | Amoxicillin | 36 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 11 |
| Nitroglycerin | Nitroglycerin | 35 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Cefdinir | Cefdinir | 33 | 20 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 32 | 32 |
| Clonazepam | Clonazepam | 31 | suppressed |
| Verapamil Er | Verapamil Hcl | 31 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Acyclovir | Acyclovir | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Simvastatin | Simvastatin | 24 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 15 |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Prednisone | Prednisone | 21 | 12 |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 16 |
| Spironolactone | Spironolactone | 20 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Dayvigo | Lemborexant | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Prolia | Denosumab | 18 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Cephalexin | Cephalexin | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Asmanex Hfa | Mometasone Furoate | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Albendazole | Albendazole | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $481.05 · 21 records | Pharmacosmos Therapeutics Inc. | ABRYSVO, CAPLYTA, COLLAGENASE SANTYL, COMIRNATY, Cologuard Collection Kit, JARDIANCE, KISUNLA, LINZESS, MONOFERRIC, MOUNJARO, PREVNAR 20, Varithena Administration Pack, Veozah, YUPELRI, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error